Mark Crossley, Indivior CEO

FDA ap­proves an­oth­er new type of opi­oid over­dose an­ti­dote nasal spray

As more than 100,000 Amer­i­cans con­tin­ue to die every year from the opi­oid over­dose epi­dem­ic, the FDA late Mon­day ap­proved an­oth­er new nasal spray that can be used in emer­gency set­tings when there’s an opi­oid over­dose for peo­ple ages 12 and old­er.

UK-based In­di­v­ior ac­quired the nasal spray, now known com­mer­cial­ly as Opvee (nalme­fene), for $145 mil­lion up­front from Opi­ant Phar­ma­ceu­ti­cals, and an­oth­er po­ten­tial $80 mil­lion if it hits cer­tain mile­stones fol­low­ing ap­proval. The spray is ex­pect­ed to hit the mar­ket in the fourth quar­ter, In­di­v­ior said.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters